|
|
 |
| |
Shareholder Information
|
THE ACTELION ANNUAL REPORT 2002 |
|
|
|
| |
|
|
|
|
|
|
|
Shareholder Information
|
| |
|
Share price
|
| |
The following table shows the reported high and low quarterly closing share price of the Actelion shares on the SWX New Market during the year 2002.
|
| |
|
High |
|
Low |
| First Quarter |
|
80.00 |
|
62.25 |
| Second Quarter |
|
80.25 |
|
54.00 |
| Third Quarter |
|
57.00 |
|
41.50 |
| Fourth Quarter |
|
66.05 |
|
43.65 |
|
|
|
|
| |
|
|
|
|
|
|
|
On 31 December 2002, the last reported closing share price was CHF 61 and market capitalization of Actelion Ltd was CHF 1.29 billion, compared with a share price of CHF 78 and market capitalization of CHF 1.6 billion the previous year. The total number of shareholders on 31 December 2002 was 4731.
|
|
|
| |
|
|
|
|
|
|
|
Listing
|
| |
Actelion Ltd is organized under Swiss law and is the holding company of the Actelion Group. The company’s initial equity funding was provided in 1998 and 1999 in two separate rounds of financing totaling CHF 66 million.
The registered shares of Actelion Ltd have been listed on the SWX New Market since April 6, 2000 (symbol: ATLN). A total of 1,000,000 primary shares were placed at the company’s Initial Public Offering at the price of CHF 260 per share raising CHF 246.6 million. On June 20, 2001, Actelion Ltd announced a 4:1 split in its shares.
On September 9, 2002 Actelion listed the company’s registered shares on the SWX Main Market. The trading symbol remains the same and the company will continue to report full quarterly figures.
|
|
|
| |
|
|
|
|
|
|
|
Investor Relations Calendar 2003
|
| |
| March 4 |
|
Media/Analyst Conference
|
| April 23 |
|
Annual General Meeting
of Shareholders |
| May 6 |
|
Q1 Results |
| August 5 |
|
Q2 Results |
| November 4 |
|
Q3 Results |
|
|
|
|
|
|
| |
Werner Henrich
Senior Vice President,
F. Hoffmann-La Roche (Pharmaceuticals Division)
Rudolf Maag
Former CEO,
Synthes-Stratec, Inc.
Fred J. Meyer
Retired Vice Chairman,
Omnicom Group
André J. Mueller
Senior Vice President
Joël Besse
Senior Principal,
Atlas Venture
|
|
Jane Royston
Branco Weiss Professor
of Entrepreneurship & Innovation,
Swiss Federal Institute
of Technology, Lausanne
Jean-Paul Clozel
Founder,
Chief Executive Officer
Robert E. Cawthorn Chairman
Retired Chairman and CEO,
Rhône-Poulenc-Rorer
Thomas Widmann Vice-Chairman
Founder |
|
|
|
|
Scientific Advisory Board
|
|
|
|
|
| |
Joël Ménard
Professor of Public Health,
University Pierre et Marie Curie, Paris
Donald Hilvert
Professor of Chemistry
at the Swiss Federal Institute of Technology (ETH), Zürich
|
|
Richard Tsien
Professor of the Department of
Molecular and Cellular Physiology,
Stanford University, Palo Alto
Craig Pratt
Professor of Medicine and Cardiology,
Baylor College of Medicine, Houston
|
|
|
|
|
|
| |
Jean-Paul Clozel
Founder,
Chief Executive Officer
Simon Buckingham
President, Head of US,
Canada, Asia Pacific
Isaac Kobrin
Senior Vice President,
Head of Clinical Development
André J. Mueller
Senior Vice President,
Chief Financial Officer
|
|
Christian Chavy
President, Head of Europe,
Middle East, Latin America
Louis de Lassence
Vice President,
Head of Corporate Services
Satoshi Tanaka
President and Representative
Director, Japan
|
|
|
|
|
|
| |
Frédéric Bodin
Senior Vice President,
Head of International Medical Marketing
Martine Clozel
Senior Vice President,
Head of Drug Discovery Pharmacology & Preclinical Development
|
|
Walter Fischli
Founder, Senior Vice President,
Head of Drug Discovery Molecular
Biology & Biochemistry |
|
|
|
